Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | FADS1 | O60427 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30231624 | 0.82 | MTNR1A (0.44) | LPLLIPGMAOAMAOBJAK2 | |
| SCHEMBL27291749 | 0.81 | CYP1A1 (0.38) | LPLLIPGMAOAMAOBNFKB1 | |
| SCHEMBL13527502 | 0.79 | LPL (0.44) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL1988244 | 0.77 | LPL (0.41) | LPLLIPGMAOAMAOBFTO | |
| SCHEMBL16048408 | 0.77 | LPL (0.37) | LPLLIPGMAOAMAOBJAK2 | |
| SCHEMBL12566009 | 0.75 | LPL (0.37) | LPLLIPGP2RX7 | |
| SCHEMBL31127488 | 0.74 | CYP1A1 (0.39) | LPLLIPGMAOAKCNA3 | |
| SCHEMBL476861 | 0.73 | BRD4 (0.38) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL476862 | 0.73 | LPL (0.44) | LPLLIPGJAK2BTK | |
| SCHEMBL29586872 | 0.73 | LPL (0.44) | LPLLIPGJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20250388560-A1 | AROMATIC COMPOUND AND USE THEREOF | HITGEN INC (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4653421-A1 | AROMATIC-RING COMPOUND AND USE THEREOF | Hitgen Inc. (CN) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025087274-A1 | AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE | 浙江海正药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2024179572-A1 | AROMATIC-RING COMPOUND AND USE THEREOF | 成都先导药物开发股份有限公司 | 2024-09-06 | — | — | WO | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20140274695-A1 | 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-amino-2-(HETEROCYCLIC)pyrimidine-4-carboxylates AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140274695-A1 | 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-amino-2-(HETEROCYCLIC)pyrimidine-4-carboxylates AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140274695-A1 | 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-amino-2-(HETEROCYCLIC)pyrimidine-4-carboxylates AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7504401-B2 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | STING1, CGAS, IRF3 | LPL 3405/4885LIPG 1271/4885MAOA 1710/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | LPL 2/4885LIPG 17/4885MAOA 182/4885 |
| US-20140274695-A1 | 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-amino-2-(HETEROCYCLIC)pyrimidine-4-carboxylates AND THEIR USE AS HERBICIDES | DDT, DDC, P2RX6 | LPL 4699/4885LIPG 4844/4885MAOA 1472/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | LPL 2/4885LIPG 8/4885MAOA 135/4885 |
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | LPL 4249/4885LIPG 4040/4885MAOA 4003/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | LPL 4302/4885LIPG 4062/4885MAOA 3986/4885 |
| US-20250388560-A1 | AROMATIC COMPOUND AND USE THEREOF | RNF213, RNF10, TRIM4 | LPL 4330/4885LIPG 4351/4885MAOA 3966/4885 |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | LPL 2540/4885LIPG 2542/4885MAOA 4382/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | LPL 2815/4885LIPG 3271/4885MAOA 4734/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | LPL 2/4885LIPG 8/4885MAOA 135/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | LPL 1895/4885LIPG 2182/4885MAOA 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.